R&D spending, according to a number of sources, continues to grow as biopharmaceutical solutions become integral to a wider range of medical maladies. Phase III clinical trials represent the critical data foundation in the new drug approval process for regulatory authorities around the worldOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.